ovarian%20cancer
OVARIAN CANCER
Ovarian cancer is a type of cancer that begins in the ovaries.
It is the 7th most common cancer in women (excluding skin cancer) and the leading cause of death from gynecologic cancer in developed countries.
The 3 histologic types of ovarian cancer are epithelial (primarily seen in women >50 years of age), germ cell (most commonly seen in women <20 years of age) and sex cord stromal (rare and produces steroid hormones).
The median age at the time of diagnosis is 63 years old and >70% present with advanced disease.

    Radiotherapy

    • Eg External beam radiation therapy, brachytherapy
    • Has a limited role in the treatment of ovarian carcinoma
    • May be useful in the palliative phase to reduce complaints due to primary tumor or metastases
      • Used for patients with symptomatic metastases to the bones, supraclavicular or inguinal node, or brain
      • Also helpful in patients with pelvic localizations (eg complaints of nerve plexus compression, bleeding, pain or stasis)
      • Palliative localized radiation therapy is also an option for recurrence treatment
    Digital Edition
    Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
    Sign In To Download
    Editor's Recommendations
    Most Read Articles
    6 days ago

    Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

    4 days ago
    Susceptibility‐guided therapy is as effective as empiric modified bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection, with both yielding excellent eradication rates, as shown in a recent trial.
    6 days ago
    It appears that long-term consumption of fish and omega-3 fatty acid does not influence the risk of incident hypertension in middle-aged and older men, suggests a US study.
    2 days ago
    Cabozantinib is not better than mitoxantrone-prednisone at relieving pain in patients with metastatic castration-resistant prostate cancer (mCRPC) with symptomatic bone metastasis, a recent study suggests.